rs1064793128
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000285071.9(FLCN):c.1379_1380del(p.Leu460GlnfsTer25) variant causes a frameshift change. The variant allele was found at a frequency of 0.00000137 in 1,461,876 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. L460L) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
ENST00000285071.9 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FLCN | NM_144997.7 | c.1379_1380del | p.Leu460GlnfsTer25 | frameshift_variant | 12/14 | ENST00000285071.9 | NP_659434.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FLCN | ENST00000285071.9 | c.1379_1380del | p.Leu460GlnfsTer25 | frameshift_variant | 12/14 | 1 | NM_144997.7 | ENSP00000285071 | P1 | |
MPRIP | ENST00000578209.5 | c.*18-2249_*18-2248del | intron_variant | 3 | ENSP00000464276 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461876Hom.: 0 AF XY: 0.00000138 AC XY: 1AN XY: 727236
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Birt-Hogg-Dube syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 02, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 25, 2023 | This sequence change creates a premature translational stop signal (p.Leu460Glnfs*25) in the FLCN gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FLCN are known to be pathogenic (PMID: 15852235). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 418213). This variant is also known as 1834delTC or 1834-5delTC. This premature translational stop signal has been observed in individuals with Birt-Hogg-Dubé syndrome (PMID: 15852235, 18234728, 20618353, 22441547, 26943385, 27220747, 28009417). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Feb 23, 2023 | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jan 11, 2022 | PP4, PM2, PS4_moderate, PVS1 - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 12, 2024 | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Also known as c.1834delTC and c.1834-5delTC; This variant is associated with the following publications: (PMID: 27220747, 26943385, 15852235, 18234728, 28009417, 36915884, 29774133) - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 10, 2021 | The c.1379_1380delTC pathogenic mutation, located in coding exon 9 of the FLCN gene, results from a deletion of two nucleotides at nucleotide positions 1379 to 1380, causing a translational frameshift with a predicted alternate stop codon (p.L460Qfs*25). This mutation has been reported in multiple individuals with clinical features of Birt-Hogg-Dubé syndrome (Schmidt LS et al. Am. J. Hum. Genet. 2005 Jun; 76(6):1023-33; Toro JR et al. J. Med. Genet. 2008 Jun; 45(6):321-31; Maffé A et al. Clin. Genet. 2011 Apr; 79(4):345-54; Furuya M et al. Am J Surg Pathol, 2012 Apr;36:589-600; Miura K et al. Surg Case Rep. 2015 Dec;1(1):17; Castellucci R et al. Urologia, 2017 Apr;84:116-120; Sager RA et al. Oncotarget, 2018 Apr;9:22220-22229). Of note, this alteration is also designated as c.1834delTC and c.1834-5delTC in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at